

July 8, 2019

Array BioPharma Announces Interim Analysis Results from the BEACON CRC Trial of BRAFTOVI + MEKTOVI + Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer at the ESMO 21st World Congress on Gastrointestinal Cancer

This information is intended to notify the press release issued on July 6 (ET) by Array BioPharma Inc. Please click <http://www.arraybiopharma.com/> for the original press release distributed by Array.

(1st paragraph of the press release)

Boulder, Colo. (July 6, 2019) – Array BioPharma Inc. (Nasdaq: ARRY) today announced the presentation of results from the Phase 3 BEACON CRC trial evaluating the combination of BRAFTOVI[®] (encorafenib), a BRAF inhibitor, MEKTOVI[®] (binimetinib), a MEK inhibitor, and ERBITUX[®] (cetuximab), an anti-EGFR antibody (BRAFTOVI Triplet), in patients with advanced BRAF^{V600E}-mutant metastatic colorectal cancer (mCRC), following one or two lines of therapy. Data presented included primary and secondary endpoints, waterfall plots describing tumor reduction, subgroup analyses, and exploratory analyses comparing overall survival (OS) of the BRAFTOVI Triplet and BRAFTOVI Doublet (BRAFTOVI and cetuximab) in a subset of patients with mature follow-up, including the first 331 randomized patients, as well as safety and tolerability.

About the Ono and Array BioPharma Collaboration

In May 2017, Ono Pharmaceutical Co., Ltd. (“ONO”) entered into the license agreement with Array BioPharma Inc. regarding BRAFTOVI[®] (encorafenib), a BRAF inhibitor and MEKTOVI[®] (binimetinib), a MEK inhibitor and received rights to develop and commercialize both products in Japan and South Korea.

About the Development Status of BRAFTOVI[®] and MEKTOVI[®]

In January 2019, ONO received the manufacturing and marketing approvals for BRAFTOVI[®] and MEKTOVI[®] and launched them for the indication of unresectable BRAF-mutant melanoma in Japan in February 2019. The products are currently in two global Phase 3 clinical trials for the treatment of patients with BRAF-mutant melanoma (COLUMBUS study) and BRAF-mutant colorectal cancer (BEACON CRC study) as a combination therapy.

Contacts:

ONO PHARMACEUTICAL CO., LTD.

Corporate Communications

public_relations@ono.co.jp